<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02569268</url>
  </required_header>
  <id_info>
    <org_study_id>Hongyu Wang</org_study_id>
    <nct_id>NCT02569268</nct_id>
  </id_info>
  <brief_title>Beijing Vascular Disease Patients Evaluation STudy</brief_title>
  <acronym>BEST</acronym>
  <official_title>Early Vascular Disease Detection System for High Risk Patients in Beijing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Shougang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Health Science Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Municipal Science &amp; Technology Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese National Natural Science Foundation Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Education of the China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Health and Family Planning Commission of the China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Shougang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arteriosclerotic vascular-related diseases have become a serious threat to human health. The
      prevention and reversal of vascular events has become an important direction of medicine.
      Early vascular disease detection system includes pulse wave velocity (PWV), carotid
      intima-media thickness (IMT) and coronary flow velocity reserve (CFVR), flow-mediated
      vasodilation (FMD), cardio-ankle vascular index (CAVI), ankle-brachial index (ABI), insulin
      resistance index (HOMA-IR), hypersensitivity C- reactive protein (hs-CRP), plasma
      homocysteine (Hcy), B-type natriuretic peptide (BNP), uric acid (UA), and so on. However,
      there is no international and domestic comprehensive study on simple and practical evaluation
      system by jointing application of these evaluation indexes to detect vascular disease.
      Combined evaluation function can simultaneously detect and evaluate vascular abnormalities,
      make up a single indicator shortcoming in clinical applications from multiple levels of
      vascular structure and function. However, all indicators testing not only cause time
      consuming, but also increase the burden on patients, resulting unnecessary waste of medical
      resources. Thus, the present study was to select appropriate indicators and effective joint,
      and establish the rating system, using the vascular system to predict the incidence of
      terminal events, and compare this system with the previous scoring system such as FRS
      (Framingham Risk Score) pros and cons.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aimed to establish vascular disease early detection system and scoring systems by
      comprehensive vascular disease risk factors and vascular function evaluation index. And
      prevention of vascular-related diseases, high-risk groups through positive lifestyle changes:
      such as lipid-lowering, smoking cessation, reversing early vascular lesions, to avoid
      end-stage vascular events.

        1. Detection of vascular function indicators include: PWV, IMT, CFVR, FMD, CAVI, ABI,
           LDL-C, HOMA-IR, hs-CRP, Hcy, BNP, UA and so on.

        2. Design the questionnaire: surveying the lifestyle, personal history, family history of
           the study population.

        3. Follow-up:2 years of observation, recording the end time of vascular events, including
           cardiovascular events (acute myocardial infarction, angina, coronary reperfusion
           therapy), stroke, heart failure, peripheral vascular disease.

        4. Statistics: Complex the factors of vascular disease, screen for an effective indicator
           to predict cardiovascular events, and based on the weight of the different factors, the
           establish the rating system, use the system to predict the incidence of vascular events
           terminal, and compare the system with the previous scoring system such as FRS
           (Framingham Risk Score).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Number of vascular diseases-related death</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of acute coronary syndrome</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>After follow-up and questionnaire, to clear the diagnosis of acute coronary syndrome assessed by guideline or CTCAE v4.0（Grade 3-5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of acute stroke</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>After follow-up and questionnaire, to clear the diagnosis of acute cerebral infarction and cerebral hemorrhage assessed by guideline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of acute heart failure</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>After follow-up and questionnaire, to clear the diagnosis of acute heart failure assessed by guideline or CTCAE v4.0（Grade 3-5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of peripheral arteriosclerosis occlusion</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>After follow-up and questionnaire, to clear the diagnosis of peripheral ischemia by guideline or CTCAE v4.0（Grade 3-5).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Vascular Disease</condition>
  <arm_group>
    <arm_group_label>exposure population</arm_group_label>
    <description>No special intervention(s) .</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires and follow-up</intervention_name>
    <description>Detecting the vascular functional parameters, questionnaire and follow-up: For 2 years or the occurrence of vascular events end time, including cardiovascular events (acute myocardial infarction, angina, coronary reperfusion therapy), stroke, heart failure, peripheral vascular disease.</description>
    <arm_group_label>exposure population</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample for DNA examination
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects such as patient or inpatient patients , aged 45-75 years ,in high-risk vascular
        events groups ,and from Dongcheng District, Shijingshan Shougang community and Mentougou
        District.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. health subjects with or without history of vascular-related diseases; or

          2. hypertension subjects; or

          3. diabetes mellitus subjects; or

          4. coronary artery disease; or

          5. cerebrovascular disease;or

          6. hyperlipidemia subjects.

        Exclusion Criteria:

          1. severe infectious diseases and inflammatory diseases;

          2. liver and kidney failure;

          3. cancer;

          4. immunological diseases;

          5. hematological system diseases。
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Wang G， He L，Hong T.Reply to letter to the editor: coronary flow velocity reserve was impaired in chronic hyperhomocysteinemia patients：why?Am J Physiol Endocrinol Metab.2011，300：E1177-E1178.</citation>
  </reference>
  <results_reference>
    <citation>Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007 Jun;25(6):1105-87. Erratum in: J Hypertens. 2007 Aug;25(8):1749.</citation>
    <PMID>17563527</PMID>
  </results_reference>
  <results_reference>
    <citation>Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation. 2006 Feb 7;113(5):664-70.</citation>
    <PMID>16461839</PMID>
  </results_reference>
  <results_reference>
    <citation>Duprez DA, Florea N, Zhong W, Grandits GA, Hawthorne CK, Hoke L, Cohn JN. Vascular and cardiac functional and structural screening to identify risk of future morbid events: preliminary observations. J Am Soc Hypertens. 2011 Sep-Oct;5(5):401-9. doi: 10.1016/j.jash.2011.05.001. Epub 2011 Jun 29.</citation>
    <PMID>21719371</PMID>
  </results_reference>
  <results_reference>
    <citation>Hirata K, Kadirvelu A, Di Tullio M, Homma S, Choy AM, Lang CC. Coronary vasomotor function is abnormal in first-degree relatives of patients with type 2 diabetes. Diabetes Care. 2007 Jan;30(1):150-3.</citation>
    <PMID>17192351</PMID>
  </results_reference>
  <results_reference>
    <citation>Ibata J, Sasaki H, Kakimoto T, Matsuno S, Nakatani M, Kobayashi M, Tatsumi K, Nakano Y, Wakasaki H, Furuta H, Nishi M, Nanjo K. Cardio-ankle vascular index measures arterial wall stiffness independent of blood pressure. Diabetes Res Clin Pract. 2008 May;80(2):265-70. doi: 10.1016/j.diabres.2007.12.016. Epub 2008 Feb 1.</citation>
    <PMID>18242761</PMID>
  </results_reference>
  <results_reference>
    <citation>Wild SH, Byrne CD, Smith FB, Lee AJ, Fowkes FG. Low ankle-brachial pressure index predicts increased risk of cardiovascular disease independent of the metabolic syndrome and conventional cardiovascular risk factors in the Edinburgh Artery Study. Diabetes Care. 2006 Mar;29(3):637-42.</citation>
    <PMID>16505519</PMID>
  </results_reference>
  <results_reference>
    <citation>Antoniades C, Antonopoulos AS, Tousoulis D, Marinou K, Stefanadis C. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J. 2009 Jan;30(1):6-15. doi: 10.1093/eurheartj/ehn515. Epub 2008 Nov 23. Review.</citation>
    <PMID>19029125</PMID>
  </results_reference>
  <results_reference>
    <citation>He L, Zeng H, Li F, Feng J, Liu S, Liu J, Yu J, Mao J, Hong T, Chen AF, Wang X, Wang G. Homocysteine impairs coronary artery endothelial function by inhibiting tetrahydrobiopterin in patients with hyperhomocysteinemia. Am J Physiol Endocrinol Metab. 2010 Dec;299(6):E1061-5. doi: 10.1152/ajpendo.00367.2010. Epub 2010 Sep 21.</citation>
    <PMID>20858749</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2015</study_first_posted>
  <last_update_submitted>May 7, 2016</last_update_submitted>
  <last_update_submitted_qc>May 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Shougang Hospital</investigator_affiliation>
    <investigator_full_name>Hongyu Wang</investigator_full_name>
    <investigator_title>Director and Professor of Vascular Medicine</investigator_title>
  </responsible_party>
  <keyword>Arteriosclerosis</keyword>
  <keyword>Vascular function</keyword>
  <keyword>Vascular disease early detection system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

